

# EptivA Therapeutics & Bayer Pharmaceuticals

EptivA Therapeutics & Bayer Pharmaceuticals enter into a contract research agreement.

EptivA Therapeutics will utilize their proprietary Personalized Analgesics® research platform on selected Bayer research targets.

Financial terms and information on selected research targets remain undisclosed.

## About EptivA Therapeutics

EptivA Therapeutics Ltd. is the first to apply a precision medicine approach to developing new pain therapeutics. The company was established in Oxford UK in 2020 by Mark J. Field (former SVP Pain R&D at Grünenthal, and a.o. key contributor to Lyrica) and Harald F. Stock (a.o. former CEO of Grünenthal, biotech co-founder and board member). EptivA's de-risked portfolio includes both, in-house assets and in-licensing options, based on its proprietary Personalized Analgesics® technology platform. Each program targets multi-modal mechanisms, with local delivery, in high-value peripheral pain patient groups – creating potent analgesics, devoid of CNS side effects. A financing in the first half of 2022 will enable further advancing the portfolio to key value inflection points, with up to three clinical proof-of-concept read-outs in the next 30 months.

For more information go to [www.eptivatx.com](http://www.eptivatx.com) or contact [harald@eptivatx.com](mailto:harald@eptivatx.com)